Medical experts sound alarm on shocking factor contributing to heart attacks — here's what you need to know
You might think air pollution only contributes to lung disease or cancer. However, medical experts are warning that it can also play a role in heart disease.
The third Illness to Wellness Summit took place in New Delhi in March 2025, with the Millennium Post reporting on the happenings and outcomes.
During the event, VMMC and Safdarjung Hospital medical superintendent Dr. Sandeep Bansal said, "Air pollution also kills by way of cardiovascular diseases."
Bansal explained that tiny air particles known as particulate matter "enter the bloodstream and can transform cholesterol in the body into oxidized cholesterol, which can lead to plaque ruptures." Plaque ruptures in the coronary arteries are the most common cause of heart attacks, according to UpToDate.
Bansal's team conducted research to reach this conclusion, according to the Post. Their study found that even a slight increase in particulate matter from one week to the next can contribute to more heart attacks.
This discovery could affect millions of people who may not know they're at risk. Air pollution comes from many human-driven sources, including factories, vehicles, and wildfires. It's especially prominent in big cities, where pollutants can get trapped by large buildings and structures.
By connecting the dots between air pollution and heart health, doctors could better identify people with an increased risk of heart disease. They might even ask patients about air pollution exposure as part of routine heart disease screenings. This could result in earlier, life-saving interventions.
The link between the two also stresses the importance of clean air policies that push for stricter rules on planet-warming pollution, such as regulations requiring automakers to put more emphasis on electric and hybrid vehicles.
Regulations are making headway in reducing air pollution. Countries participating in the Global Methane Pledge — including the United States — have committed to reducing methane emissions by at least 30% by 2030. The Environmental Protection Agency has also cracked down on vehicle modification device manufacturers with hefty fines for producing polluting products.
However, billions of people don't have the resources or tools to measure air quality and determine whether the air they breathe is healthy. There's still a long way to go to improve air quality and save lives.
Do you worry about air pollution in and around your home?
Yes — always
Yes — often
Yes — sometimes
No — never
Click your choice to see results and speak your mind.
For individuals, one impactful way to cut down on air pollution and protect both yourself and your community is by switching to an electric vehicle. You can also upgrade to greener everyday items, like using efficient appliances, opting for electric yard equipment instead of gas-powered, and turning off your car whenever possible instead of letting it idle.
Join our free newsletter for weekly updates on the latest innovations improving our lives and shaping our future, and don't miss this cool list of easy ways to help yourself while helping the planet.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Wire
4 days ago
- Business Wire
Wolters Kluwer Again Recognized as Clinical Decision Support Leader
WALTHAM, Mass.--(BUSINESS WIRE)-- Wolters Kluwer Health has once again been identified as one of the top two companies in the new Frost Radar™ report on Clinical Decision Support Systems (CDSS). Evaluating over 60 companies, the Frost Radar spotlights 10; Wolters Kluwer was the only one named both a 'Company to Action' and the market leader for innovation. The company was also a leader in the 2023 report. Wolters Kluwer Health has been identified as one of the top two companies in the new Frost Radar™ report on Clinical Decision Support Systems (CDSS) and the only one named both a 'Company to Action' and the market leader for innovation. Share According to the Frost report, the top-right Radar position of Wolters Kluwer shows it 'has firmly established itself as a leader in the CDSS market, with impressive R&D investment, and recent and upcoming product launches. The company's strategic integration of emerging technologies, particularly Gen AI, has positioned it at the forefront of next-generation CDSS solutions.' The report also recognizes the company's redefinition of the CDSS category with its introduction of UpToDate Enterprise Edition stating it 'is designed to align buyers, administrators, and care teams on a singular platform. This strategic alignment is key in enhancing care delivery and realizing superior returns on investment. With advanced on-demand analytics, this edition offers system-level insights into product usage, community trends, education needs, and the overarching impact of UpToDate on healthcare systems.' 'The Frost Radar is a deep dive into the CDSS market and its vendors. Based on our analysis, Wolters Kluwer has achieved significant growth for its solutions by focusing on innovation and customer-centric solutions,' said Dr. Rishi Pathak, Global Director of Healthcare & Life Sciences, Frost & Sullivan. 'That, combined with their strategy to increase the reach of UpToDate through integration into the clinician workflow and the intention to address adjacent operational and financial workflows, puts them in the leadership position.' Wolters Kluwer Health recently announced the integration of UpToDate with several ambient AI leaders, including Abridge, Suki, Microsoft and others. 'Being named the innovation leader in the Frost Radar reinforces our focus on innovation and interconnectivity and validates our commitment to transforming healthcare through product innovation and strategic partnerships,' said Greg Samios, CEO of Wolters Kluwer Health. 'We remain dedicated to helping providers make faster, smarter decisions across the care continuum, while enabling organizations to maximize their UpToDate investment through insightful analytics, harmonized content, seamless integration, and AI-enhanced features.' Learn more about Wolters Kluwer in the Frost Radar on CDSS. About Wolters Kluwer Wolters Kluwer (EURONEXT: WKL) is a global leader in information, software solutions and services for professionals in healthcare; tax and accounting; financial and corporate compliance; legal and regulatory; corporate performance and ESG. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with technology and services. Wolters Kluwer reported 2024 annual revenues of €5.9 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 21,600 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands. For more information, visit follow us on LinkedIn, Facebook, YouTube and Instagram.
Yahoo
29-05-2025
- Yahoo
Wolters Kluwer appoints Greg Samios as CEO of Health division
PRESS RELEASE Wolters Kluwer appoints Greg Samios as CEO of Health division Experienced healthcare executive has track record of driving innovation and delivering results Alphen aan den Rijn — May 29, 2025 — Wolters Kluwer, a global leader in information solutions, software, and services for professionals, has named Greg Samios as Chief Executive Officer of its Health division, effective June 1. Samios succeeds Stacey Caywood, who became a Member of the Executive Board of Wolters Kluwer on May 15, 2025. A seasoned healthcare executive with more than twenty-five years of experience, Samios has served as Executive Vice President of the Health division's two largest business units, Clinical Effectiveness and Health Learning, Research, and Practice. While a Health division leader, Samios has driven growth in Wolters Kluwer's leading clinical decision support and clinical drug information products, UpToDate and Medi-Span. He also led the introduction of generative AI into the company's healthcare products and solidified partnerships with leading digital health companies. In a prior role at Wolters Kluwer, Samios served as Executive Vice President of the Legal & Regulatory U.S. business. His career experience before joining Wolters Kluwer included several health-focused positions at Elsevier spanning more than ten years. He earned a Master of Business Administration from Duke University Fuqua School of Business and graduated with a B.S. and M.S. in Engineering from the University of Rochester. 'We are delighted to name Greg Samios as the new CEO of Wolters Kluwer Health,' said Nancy McKinstry, Chief Executive Officer and Chair of the Executive Board for Wolters Kluwer. 'Our large, global Health division requires an experienced leader to continue driving innovation and adapting to market challenges. We are confident that Greg has the right combination of experience and passion to deliver on our strategy and drive incremental value for our customers and growth for our business.' Wolters Kluwer Health supports professionals across healthcare with trusted advanced technology, evidence-based solutions, research, and life-long learning. ###About Wolters KluwerWolters Kluwer (EURONEXT: WKL) is a global leader in information solutions, software and services for professionals in healthcare; tax and accounting; financial and corporate compliance; legal and regulatory; corporate performance and ESG. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with technology and services. Wolters Kluwer reported 2024 annual revenues of €5.9 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 21,900 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands. Wolters Kluwer shares are listed on Euronext Amsterdam (WKL) and are included in the AEX, Euro Stoxx 50 and Euronext 100 indices. Wolters Kluwer has a sponsored Level 1 American Depositary Receipt (ADR) program. The ADRs are traded on the over-the-counter market in the U.S. (WTKWY). For more information, visit follow us on LinkedIn, Facebook, YouTube and Instagram. Media Investor/Analyst Stefan Kloet Meg Geldens Associate Director Vice President Global Communications Investor Relations press@ ir@ t: +316 1233 657 Andre Rebelo Wolters Kluwer Health Director, External Communications t: +1 781 392 2411 Forward-looking Statements and Other Important Legal InformationThis report contains forward-looking statements. These statements may be identified by words such as 'expect', 'should', 'could', 'shall' and similar expressions. Wolters Kluwer cautions that such forward-looking statements are qualified by certain risks and uncertainties that could cause actual results and events to differ materially from what is contemplated by the forward-looking statements. Factors which could cause actual results to differ from these forward-looking statements may include, without limitation, general economic conditions; conditions in the markets in which Wolters Kluwer is engaged; conditions created by pandemics; behavior of customers, suppliers, and competitors; technological developments; the implementation and execution of new ICT systems or outsourcing; and legal, tax, and regulatory rules affecting Wolters Kluwer's businesses, as well as risks related to mergers, acquisitions, and divestments. In addition, financial risks such as currency movements, interest rate fluctuations, liquidity, and credit risks could influence future results. The foregoing list of factors should not be construed as exhaustive. Wolters Kluwer disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Attachment 2025.05.29 Wolters Kluwer appoints Greg Samios as CEO of Health divisionSign in to access your portfolio
Yahoo
23-04-2025
- Yahoo
Insurance change could jeopardize 12-year-old's life-saving treatment
(NewsNation) — The life of 12-year-old Maddie Krelle, who has life-threatening food allergies and severe asthma, depends on in-office asthma injections, and she is at high risk for anaphylaxis. Her health insurance company, Blue Cross Blue Shield of Illinois, will begin requiring prior authorization for in-office treatments, according to a release. Blue Cross Blue Shield offices in Texas, Oklahoma, New Mexico and Montana will likely follow next. The insurance company would prefer patients to self-administer the medication at home rather than in a medical setting, even if a doctor may not agree. The sixth grade student is a patient who will be directly impacted by these policy changes once they go into effect. Krelle takes the allergy medication Xolair, which is one of the drugs listed under Blue Cross Blue Shield's new policy. Krelle is pushing to keep her coverage for in-office shots, saying she's afraid to self-administer them, even with the assistance of a caregiver. Florida woman who told insurance compant 'delay, deny, depose' has charge dropped 'I would be really scared to do them at home because it would be so much more of a risk of having an allergic reaction because there wouldn't be any people to supervise you,' Krelle told NewsNation. Krelle's physician, Dr. Priya Bansal, is an allergist and immunologist in Illinois. She said the main concern is anaphylaxis, where a patient has a bad reaction and could have trouble breathing and swallowing. 'The sad thing is that is the reason that Maddie is taking it right? She's trying to prevent that from happening to herself for a food allergy,' Bansal said. Bansal added, 'Obviously, for somebody who's been through that type of reaction in their life, they don't have any interest in going through that type of reaction again.' In a statement to NewsNation, Blue Cross Blue Shield of Illinois stated the change was 'made with the interests of our members in mind—promoting access to treatment that is convenient and effective.' Dr. Purvi Parikh, a New York-based immunologist and allergist with the Allergy and Asthma Network, who does not treat Krelle, said that with any injectable medication, there is a possible risk of anaphylaxis. 'In fact, Xolair has a boxed warning on it for anaphylaxis, which is the most serious the FDA gives out,' she said. '… If you do not inject it correctly, you can harm yourself or not get the correct dose. A physician should determine if a patient can safely take the medication at home, not an insurance company.' Krelle plans to appeal the policy. Dr. Bansal said her practice has 38 patients with Blue Cross Blue Shield whose authorizations are going to expire from April 2025 all the way through March 2026. Patients can submit an appeal to the insurance company. However, Parikh says, 'often the appeals go nowhere. Every time I appeal, they still deny. They don't care. It's a rigged system that's meant to make both the doctor and patient give up.' Bansal argued a similar point. Texas legislation considers AI rules for health insurance claimsxol 'I have to prove that she (Maddie) has anaphylaxis to something else in order for her to get it (the medication) at home or that the caregiver is unable to do it. Again, how am I going to provide that burden of proof?' she said. A written statement provided to NewsNation on Friday from David Van de Walle, a spokesperson for Blue Cross Blue Shield of Illinois, read, 'These medications already have been covered under the standard pharmacy benefit for members with pharmacy coverage. There is not one singular pharmacy benefit manager or specialty pharmacy that would be used by all our members eligible for self-administration of these asthma medications.' Dr. Marion Mass, a pediatrician in the Philadelphia suburbs and patient and physician advocate, told NewsNation that as long as there is no risk for anaphylaxis, drugs like Xolair can safely be administered at home. But she cautioned that it is important for health care insurance companies to be transparent. 'If the drug is able to be administered safely in the home environment, after ensuring by first injection that there is no risk for anaphylaxis, this can save significant money on the cost to administer in a hospital or clinic setting,' she said. However, Mass said that Americans deserve the right to 'follow the money' on insurance companies and highlighted the Blue Cross Blue Shield of Illinois policy that states, 'Pharmacy benefit coverage guidelines will continue to apply and may include limiting patients to using a network specialty pharmacy.' Blue Cross Blue Shield of Illinois has their own in-house Pharmacy Benefit Manager (PBM), which Mass said creates lists of drugs covered on a tiered basis. But PBMs also have an exemption from the anti-kickback statute, Mass added. 'The PBM can make formulary decisions and even create a monopoly situation for any class of drug based on the colossal conflict of interest of a kickback instead of affordability for the patient,' Mass said. Mass explained it's based on the cost of the drug, which could incentivize insurance companies to choose a costlier medication, meaning, 'It is the patient, the vulnerable sick patient, who gets stuck with a bigger bill.' Blue Cross Blue Shield of Illinois did not respond to questions about the PBM. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.